← board
AEON
distress 9/10 · high distress / dilution risk$0.26-4%today-81% from 52w high
Revenue
pre-revenue
Liquidity
$6M
Runway
0.5 yrs
Shares 1y
+2159%
Price & events
-77.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
-4.1%
1D
-11.2%
1W
-61.9%
1M
-74.7%
3M
-76.3%
6M
-68.6%
1Y
-99.9%
2Y
—
5Y
-100.0%
All
Overview
- Market Cap
- $6.93M
- Volume
- 89.57K
- 52 Week Range
- $0.26 – $1.40
- Total Shares
- 26.31M
- Float Shares
- 6.93M
- Short %
- 1.15%
- % Held by Insiders
- 76.68%
- % Held by Institutions
- 5.45%
- RVOL
- 0.04x
- Beta
- 0.61
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 5
- 2026-01-21fda agreementABP-450 · Held BPD Type 2a meeting with FDA; awaiting official meeting minutes.SEC 8-K
- January 21, 2026conferencedata presentationsecondaryABP-450 · FDA Type 2a meeting to align on analytical pathway for ABP-450 biosimilar development.SEC 8-K
- second half of 2025conferencedata presentationsecondaryABP-450 · FDA BPD Type 2a meeting targetedSEC 8-K
- 2025-12-15partnershipEntered exchange agreement with Daewoong to exchange convertible notes for equity and new notes.SEC 8-K
- 3Q 2025readoutABP-450 · Primary structure and functional dataSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2025-10-08Aegis CapitalBuy
- 2024-10-01HC Wainwright & Co.Buy
- 2024-08-14HC Wainwright & Co.Buy
- 2024-07-10HC Wainwright & Co.Buy
Competitors
- none identified
Recent news
- 2026-07-21Stonepine Capital group discloses 9.9% AEON Biopharma (AEON) ownership via stock and warrants - Stock Titan
- 2026-07-15AEON Biopharma (NYSE American: AEON) sells stock and milestone-tied warrants - Stock Titan
- 2026-07-14AEON Biopharma Announces Pricing of Upsized $13.75 Million Public Offering with Accompanying Milestone Warrants Providing Potential for Additional Future Funding - marketscreener.com
- 2026-07-14AEON Biopharma Could Raise $29.6M More Through Warrants - Stock Titan
- 2026-07-14AEON Biopharma (AEON) Slides 10% Towards Key Support as Selling Pressure Intensifies - Fibonacci Time Zone - dars.gov.et
- 2026-07-14AEON Biopharma, Inc. SEC Filing (Jul 14, 2026) - Stock Titan
- 2026-07-09AEON Biopharma (NASDAQ: AEON) revises S-1 filing fee table for milestone warrants - Stock Titan
- 2026-07-08AEON Biopharma (AEON) files S-1 for $11M stock sale plus milestone warrants - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.